Logo image of ZEAL

Zealand Pharma AS (ZEAL) Stock Price, Quote, News and Overview

NASDAQ:ZEAL - Nasdaq - US98920Y3045 - ADR - Currency: USD

17.59  +0.21 (+1.21%)

ZEAL Quote, Performance and Key Statistics

Zealand Pharma AS

NASDAQ:ZEAL (9/29/2022, 8:02:19 PM)

17.59

+0.21 (+1.21%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High33.42
52 Week Low9.93
Market Cap811.25M
Shares46.12M
Float38.55M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)11-09 2022-11-09
IPO11-01 2010-11-01


ZEAL short term performance overview.The bars show the price performance of ZEAL in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 20 30

ZEAL long term performance overview.The bars show the price performance of ZEAL in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40

The current stock price of ZEAL is 17.59 USD. In the past month the price decreased by -5.35%. In the past year, price decreased by -48.7%.

Zealand Pharma AS / ZEAL Daily stock chart

ZEAL Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.97 357.10B
AMGN AMGEN INC 15.29 162.72B
GILD GILEAD SCIENCES INC 23.85 137.00B
VRTX VERTEX PHARMACEUTICALS INC 1669.79 124.40B
REGN REGENERON PHARMACEUTICALS 15.34 76.56B
ARGX ARGENX SE - ADR N/A 39.16B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.32B
BNTX BIONTECH SE-ADR N/A 28.77B
ONC BEIGENE LTD-ADR N/A 27.25B
NTRA NATERA INC N/A 21.43B
BIIB BIOGEN INC 8.54 20.49B
SMMT SUMMIT THERAPEUTICS INC N/A 16.31B

About ZEAL

Company Profile

ZEAL logo image Zealand Pharma A/S is a biotechnology company, which engages in the discovery, design, and development of peptide based medicines. The firm is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The firm's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The firm operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.

Company Info

Zealand Pharma AS

Sydmarken 11

Soeborg 2860 DK

CEO: Emmanuel Dulac

Employees: 237

Company Website: https://www.zealandpharma.com/

Phone: 4588773600.0

Zealand Pharma AS / ZEAL FAQ

What is the stock price of Zealand Pharma AS today?

The current stock price of ZEAL is 17.59 USD. The price increased by 1.21% in the last trading session.


What is the ticker symbol for Zealand Pharma AS stock?

The exchange symbol of Zealand Pharma AS is ZEAL and it is listed on the Nasdaq exchange.


On which exchange is ZEAL stock listed?

ZEAL stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for Zealand Pharma AS stock?

14 analysts have analysed ZEAL and the average price target is 28.31 USD. This implies a price increase of 60.93% is expected in the next year compared to the current price of 17.59. Check the Zealand Pharma AS stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is Zealand Pharma AS worth?

Zealand Pharma AS (ZEAL) has a market capitalization of 811.25M USD. This makes ZEAL a Small Cap stock.


How many employees does Zealand Pharma AS have?

Zealand Pharma AS (ZEAL) currently has 237 employees.


What are the support and resistance levels for Zealand Pharma AS (ZEAL) stock?

Zealand Pharma AS (ZEAL) has a support level at 16.62 and a resistance level at 19.15. Check the full technical report for a detailed analysis of ZEAL support and resistance levels.


Is Zealand Pharma AS (ZEAL) expected to grow?

The Revenue of Zealand Pharma AS (ZEAL) is expected to grow by 13.79% in the next year. Check the estimates tab for more information on the ZEAL EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy Zealand Pharma AS (ZEAL) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does Zealand Pharma AS (ZEAL) stock pay dividends?

ZEAL does not pay a dividend.


When does Zealand Pharma AS (ZEAL) report earnings?

Zealand Pharma AS (ZEAL) will report earnings on 2022-11-09.


What is the Price/Earnings (PE) ratio of Zealand Pharma AS (ZEAL)?

Zealand Pharma AS (ZEAL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.45).


ZEAL Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to ZEAL. When comparing the yearly performance of all stocks, ZEAL is one of the better performing stocks in the market, outperforming 70.51% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ZEAL Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ZEAL. ZEAL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ZEAL Financial Highlights

Over the last trailing twelve months ZEAL reported a non-GAAP Earnings per Share(EPS) of -3.45. The EPS increased by 3.09% compared to the year before.


Industry RankSector Rank
PM (TTM) -583.94%
ROA -94.74%
ROE N/A
Debt/Equity 0.93
Chartmill High Growth Momentum
EPS Q2Q%-60.7%
Sales Q2Q%-22.36%
EPS 1Y (TTM)3.09%
Revenue 1Y (TTM)25.74%

ZEAL Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 86% to ZEAL. The Buy consensus is the average rating of analysts ratings from 14 analysts.

For the next year, analysts expect an EPS growth of -5.24% and a revenue growth 13.79% for ZEAL


Ownership
Inst Owners0%
Ins OwnersN/A
Short Float %N/A
Short RatioN/A
Analysts
Analysts85.71
Price Target28.31 (60.94%)
EPS Next Y-5.24%
Revenue Next Year13.79%